V. Brunetti

First name

V.

Middle name

C.

Last name

Brunetti

Tan, E. H., Rathod-Mistry, T., . Y. Strauss, V., O'Kelly, J., Giorgianni, F., Baxter, R., et al. (2024). Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases. J Bone Miner Res. http://doi.org/10.1093/jbmr/zjae059

View

Brunetti, V. C., St-Jean, A., Dell'Aniello, S., Fisher, A., H. Y. Yu, O., Bugden, S. C., et al. (2022). Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom. Bmc Endocr Disord, 22, 241. http://doi.org/10.1186/s12902-022-01140-1

View

Brunetti, V. C., H. Y. Yu, O., Platt, R. W., & Filion, K. B. (2022). The Association of Long-Acting Insulin Analogue Use Versus Neutral Protamine Hagedorn Insulin Use With Major Adverse Cardiovascular Events Among Individuals With Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Obes Metab. http://doi.org/10.1111/dom.14802

View

Brunetti, V. C., Reynier, P., Azoulay, L., H. Y. Yu, O., Ernst, P., Platt, R. W., & Filion, K. B. (2021). SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study. Pharmacoepidemiol Drug Saf. http://doi.org/10.1002/pds.5192

View

Brunetti, V. C., H. Y. Yu, O., Platt, R. W., & Filion, K. B. (2021). Initiation of four basal insulins and subsequent treatment modification in people treated for type 2 diabetes in the United Kingdom: Changes over the period 2003-2018. Diabet Med. http://doi.org/10.1111/dme.14603

View